Abstract
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), which is capable of selectively inducing apoptosis of cancer cells, is a potential targeted drug for cancer therapy. Many clinical trials have verified the safety, tolerability, and therapeutic efficacy of TRAIL or TRAIL agonists in patients. However, the resistance to TRAIL in multiple cancer cells resulted in limited treatment response and poor prognosis. In this review, the molecular mechanisms of TRAIL resistance in cancer cells are summarized. How TRAIL receptors, structure of the cellular membrane, the Protein Kinase B (Akt) and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) pathways involve in regulating TRAIL resistance is described. A full understanding of the exact molecular mechanisms of TRAIL resistance in cancer cells could help to design more suitable strategies and new drugs to overcome TRAIL resistance and obtain better therapeutic outcomes.
Keywords: TRAIL, molecular mechanism, resistance, death receptor, AKt, lipid raft, NF-κB, cancer.
Current Pharmaceutical Design
Title:The Molecular Mechanisms of TRAIL Resistance in Cancer Cells: Help in Designing New Drugs
Volume: 20 Issue: 42
Author(s): Feng Wang, Junsheng Lin and Ruian Xu
Affiliation:
Keywords: TRAIL, molecular mechanism, resistance, death receptor, AKt, lipid raft, NF-κB, cancer.
Abstract: Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), which is capable of selectively inducing apoptosis of cancer cells, is a potential targeted drug for cancer therapy. Many clinical trials have verified the safety, tolerability, and therapeutic efficacy of TRAIL or TRAIL agonists in patients. However, the resistance to TRAIL in multiple cancer cells resulted in limited treatment response and poor prognosis. In this review, the molecular mechanisms of TRAIL resistance in cancer cells are summarized. How TRAIL receptors, structure of the cellular membrane, the Protein Kinase B (Akt) and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) pathways involve in regulating TRAIL resistance is described. A full understanding of the exact molecular mechanisms of TRAIL resistance in cancer cells could help to design more suitable strategies and new drugs to overcome TRAIL resistance and obtain better therapeutic outcomes.
Export Options
About this article
Cite this article as:
Wang Feng, Lin Junsheng and Xu Ruian, The Molecular Mechanisms of TRAIL Resistance in Cancer Cells: Help in Designing New Drugs, Current Pharmaceutical Design 2014; 20 (42) . https://dx.doi.org/10.2174/1381612820666140929100735
DOI https://dx.doi.org/10.2174/1381612820666140929100735 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Advances in the Molecular Pathogenesis of Inflammatory Bowel Disease.
This thematic issue will emphasize the recent breakthroughs in the mechanisms of Inflammatory bowel disease (IBD) pathogenesis and devotes some understanding of both Crohn’s and ulcerative colitis. It is expected to include studies about cellular and genetic aspects, which help to precipitate the disease, and the immune system-gut microbiome relations ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Aptamer-based Cell Recognition and Detection
Current Analytical Chemistry Paris polyphylla: Chemical and Biological Prospectives
Anti-Cancer Agents in Medicinal Chemistry Stilbenes and Xanthones from Medicinal Plants as Potential Antitumor Agents
Current Bioactive Compounds Melanoma: The Radiotherapeutic Point of View; Review of the Current Literature
Reviews on Recent Clinical Trials PET/CT Based Dose Planning in Radiotherapy
Current Medical Imaging 2-Pyrazolines as Biologically Active and Fluorescent Agents, An Overview
Anti-Cancer Agents in Medicinal Chemistry Modulation of intracellular pH in human ovarian cancer.
Current Molecular Medicine Recent Trends in Computer-aided Drug Design for Anti-cancer Drug Discovery
Current Topics in Medicinal Chemistry What is Currently the Best Radiopharmaceutical for the Hybrid PET/CT Detection of Recurrent Medullary Thyroid Carcinoma?
Current Radiopharmaceuticals Involvement of Cytoskeleton in AhR-Dependent CYP1A1 Expression
Current Drug Metabolism Ribonucleotide Reductase: A Mechanistic Portrait of Substrate Analogues Inhibitors
Current Medicinal Chemistry Neural Stem Cell Niches in Health and Diseases
Current Pharmaceutical Design Chromatin Remodeling Agents for Cancer Therapy
Reviews on Recent Clinical Trials A Review on Structures and Functions of Bcl-2 Family Proteins from Homo sapiens
Protein & Peptide Letters Tubulin Maytansine Site Binding Ligands and their Applications as MTAs and ADCs for Cancer Therapy
Current Medicinal Chemistry Applications of Aptamers in Targeted Imaging: State of the Art
Current Topics in Medicinal Chemistry Epothilones: From Discovery to Clinical Trials
Current Topics in Medicinal Chemistry Advances in Synergistic Combinations of Chinese Herbal Medicine for the Treatment of Cancer
Current Cancer Drug Targets Nucleo-Cytoplasmic Transport of Proteins as a Target for Therapeutic Drugs
Current Medicinal Chemistry Infection, Stem Cells and Cancer Signals
Current Pharmaceutical Biotechnology